Bank of Nova Scotia Reduces Position in Danaher Co. (NYSE:DHR)

Bank of Nova Scotia decreased its position in Danaher Co. (NYSE:DHRFree Report) by 0.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 274,419 shares of the conglomerate’s stock after selling 507 shares during the period. Bank of Nova Scotia’s holdings in Danaher were worth $63,462,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. Cape Investment Advisory Inc. acquired a new stake in shares of Danaher during the fourth quarter worth about $25,000. BKM Wealth Management LLC acquired a new stake in Danaher during the 4th quarter valued at approximately $27,000. Wetzel Investment Advisors Inc. purchased a new stake in shares of Danaher in the 4th quarter valued at $29,000. Rakuten Securities Inc. acquired a new stake in shares of Danaher in the fourth quarter worth $36,000. Finally, Financial Connections Group Inc. purchased a new position in shares of Danaher during the fourth quarter worth $41,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Transactions at Danaher

In other Danaher news, CEO Rainer Blair sold 9,005 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the sale, the chief executive officer now owns 106,990 shares in the company, valued at approximately $28,352,350. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Danaher news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Rainer Blair sold 9,005 shares of Danaher stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the transaction, the chief executive officer now owns 106,990 shares in the company, valued at approximately $28,352,350. The disclosure for this sale can be found here. Over the last three months, insiders have sold 148,783 shares of company stock valued at $37,536,717. Corporate insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. TD Cowen upped their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Bank of America upped their target price on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. Barclays lifted their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 24th. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and upped their price objective for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. Finally, Robert W. Baird boosted their target price on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $267.31.

Get Our Latest Stock Analysis on DHR

Danaher Price Performance

Shares of DHR traded up $4.06 during mid-day trading on Friday, hitting $256.80. 4,801,089 shares of the company were exchanged, compared to its average volume of 2,251,350. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $268.98. The stock has a market cap of $190.21 billion, a price-to-earnings ratio of 43.53, a price-to-earnings-growth ratio of 3.93 and a beta of 0.83. The company has a 50 day moving average of $250.39 and a 200-day moving average of $241.04.

Danaher (NYSE:DHRGet Free Report) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the prior year, the firm earned $2.36 earnings per share. The business’s revenue was down 2.6% compared to the same quarter last year. Analysts expect that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio (DPR) is 18.31%.

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read More

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.